Mgat5 Deficient Animal Model for Autoimmune Disease Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and treatment methods for multiple sclerosis (MS) and other autoimmune diseases are inadequate due to their complex etiology and lack of effective interplay between environmental and genetic factors, leading to disparate and ineffective pharmaceutical agents and markers.
Innovation Solution
Development of a nonhuman animal model with defective N-glycan processing pathways, specifically targeting Mgat5 gene alleles, to mimic autoimmune demyelinating diseases like MS, and use of compounds that modulate N-glycan processing to inhibit disease pathology, including the use of agonists and metabolites to increase Mgat5 modified glycan levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic and treatment methods for MS are used, then various pharmaceutical agents and markers are available, but they are disparate and ineffective due to complex etiology and lack of effective interplay between environmental and genetic factors
Solution Approach 1:
The patent uses N-glycan structures as intermediary molecules that mediate between genetic factors (Mgat5 gene) and autoimmune disease pathology. These glycans serve as a bridge connecting genetic predisposition to disease manifestation, providing a tangible target for diagnosis and treatment that unifies the complex etiological factors into a coherent therapeutic approach.
Solution Approach 2:
The invention changes the parameter of glycan structure modification through Mgat5 enzyme activity. By modifying N-glycan structures (adding β1,6GlcNAc branches) through enzymatic action or metabolic precursors, the patent transforms the biochemical parameter of glycan configuration to prevent T-cell activation and autoimmune disease, thereby improving treatment effectiveness through a specific biochemical parameter change.
2Measurement precision
If a nonhuman animal model with defective N-glycan processing pathways is developed, then disease pathways can be effectively screened and targeted treatments identified, but the model requires complex genetic modification and metabolic supplementation
Solution Approach 1:
The patent applies preliminary action by pre-modifying the N-glycan processing pathway in animal models through genetic modification (Mgat5 deficiency) before disease induction. This preliminary biochemical alteration creates a predisposed state that accurately models human autoimmune disease susceptibility, allowing precise disease pathway screening without requiring complex concurrent interventions during disease development.
Solution Approach 2:
The invention creates a simplified copy of the human disease mechanism by replicating the core defect (N-glycan processing deficiency) in animal models. Rather than copying the entire complex human autoimmune disease system, the patent captures the essential pathological feature (defective Mgat5 function leading to altered N-glycans) in a tractable animal model that can be easily manipulated and studied.
3Reliability
If compounds that modulate N-glycan processing are used to increase Mgat5 modified glycan levels, then disease pathology is inhibited, but the treatment requires specific metabolic supplementation
Solution Approach 1:
The patent applies self-service by enabling the animal model's own metabolic pathways to produce the therapeutic effect. By supplementing with simple metabolic precursors (UDP-GlcNAc, GlcNAc, or dietary components that feed into the hexosamine pathway), the system activates the animal's endogenous Mgat5 enzyme to produce protective N-glycans autonomously, rather than requiring direct administration of complex therapeutic molecules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach allows for effective screening of compounds and potential treatments for MS and other autoimmune diseases by modeling disease pathways and modulating N-glycan processing, providing a more targeted and effective diagnostic and therapeutic strategy.
Implementation Method 1
Mgat5 is a potent negative regulator of TCR signaling, T-cell proliferation, TH1 differentiation and autoimmunity. Mgat5-modified N-glycans are extended with poly-N-acetyllactosamine sequences
Implementation Method 2
Mgat5 N-glycans on T cell receptor (TCR) bind multi-valent galectins, thus restricting TCR recruitment into the immune synapse
Data Source
AI summary
Contemplated compositions and methods are directed to prevent and/or treat various autoimmune diseases that are typically associated with glycan dysregulation, and especially autoimmune demyelinating diseases. Further especially contemplated aspects include animal models and systems for screening compounds to treat and/or prevent such diseases.